Lucius Sotorasib – Online kaufen

MYR 1,213.34

2,700+ terjual
Harga Promosi

Farmasi fizikal Hong Kong dengan jaminan produk tulen 100%

Sorotan Produk

Sotorasib is a prescription medicine that targets KRAS G12C mutant proteins and received accelerated FDA approval in the United States on May 28, 2021. Use only as directed by a physician.

Jaminan Perkhidmatan

Penghantaran Rentas SempadanFarmasi BerlesenDisemak Ahli FarmasiJaminan Ketulenan

Spesifikasi

Spesifikasi
120mg*56 tablets
Pengilang
Lucius Pharmaceuticals
Penghantaran
Hong Kong

10000 in stock

Maklumat Produk

Nama Inggeris
Sotorasib
Nama Generik
Sotorasib

Spesifikasi

Spesifikasi
120mg*56 tablets
Pengilang
Lucius Pharmaceuticals
Penghantaran
Hong Kong

Butiran Penuh

Indikasi

Indicated for certain cases of non-small cell lung cancer (NSCLC) and KRAS G12C-mutated metastatic colorectal cancer (mCRC).

Mekanisme Tindakan

Sotorasib Mekanisme Tindakan Mekanisme Tindakan ,

Dos dan Cara Penggunaan

2 Recommended dosage: (NSCLC) (mCRC) , 960 mg (2.2) , (2.2) 2.1 KRAS G12C NSCLC KRAS G12C , LUMAKRAS NSCLC , [ (14.1)] KRAS G12C (mCRC) KRAS G12C , (mCRC) [ (14.2)] FDA KRAS G12C

Langkah Berjaga-jaga

5 Langkah Berjaga-jaga 3 , 3 , , LUMAKRAS (2.3, 5.1) (ILD)/ ILD/ , LUMAKRAS ILD/ , (2.3, 5.2) 5.1 LUMAKRAS , (ALT) (AST) , LUMAKRAS 960 mg [ (6.1)],27% , 16% ≥10

Package Insert

Ingredients

11 Description RAS GTP C₃₀H₃₀F₂N₆O₃, 560.6 g/mol 6- -7-(2- -6- )-(1M)-1-[4- -2-( -2- ) -3- ]-4-[(2S)-2- -4-( -2- ) -1- ] [2,3-d] -2(1H)- pKa 8.06 4.56 pH 1.2 6.8 ,sotorasib 1.3 mg/mL 0.03 mg/mL

Appearance

3. 320 , , , , , “AMG”, “320” 240 , , , , , “AMG”, “240” 120 , , , , , “AMG”, “120” 320 240 120

Indications

Indicated for certain cases of non-small cell lung cancer (NSCLC) and KRAS G12C-mutated metastatic colorectal cancer (mCRC).

Dos dan Cara Penggunaan

2 Recommended dosage: (NSCLC) (mCRC) , 960 mg (2.2) , (2.2) 2.1 KRAS G12C NSCLC KRAS G12C , LUMAKRAS NSCLC , [ (14.1)] KRAS G12C (mCRC) KRAS G12C , (mCRC) [ (14.2)] FDA KRAS G12C

Precautions

5 Langkah Berjaga-jaga 3 , 3 , , LUMAKRAS (2.3, 5.1) (ILD)/ ILD/ , LUMAKRAS ILD/ , (2.3, 5.2) 5.1 LUMAKRAS , (ALT) (AST) , LUMAKRAS 960 mg [ (6.1)],27% , 16% ≥10

Clinical Pharmacology

12 12.1 Mekanisme Tindakan KRAS G12C ,KRAS G12C RAS GTP KRAS KRAS G12C , , , KRAS KRAS G12C KRAS KRAS G12C, , , KRAS G12C

Clinical Studies

14 14.1 KRAS G12C LUMAKRAS CodeBreaK 100 [NCT03600883] KRAS G12C , / , ECOG 0 1, RECIST v1.1 QIAGEN therascreen® KRAS RGQ PCR , KRAS G12C 126 ,2 2%

Ulasan Produk (15)

Filter: All Reviews
4.8★★★★★
+o***e· 3 weeks ago
★★★★
+t***3· 1 months ago
Pembelian Disahkan
★★★★★

Penerangan produk

Indikasi

Indicated for certain cases of non-small cell lung cancer (NSCLC) and KRAS G12C-mutated metastatic colorectal cancer (mCRC).

Mekanisme Tindakan

Sotorasib Mekanisme Tindakan Mekanisme Tindakan ,

Dos dan Cara Penggunaan

2 Recommended dosage: (NSCLC) (mCRC) , 960 mg (2.2) , (2.2) 2.1 KRAS G12C NSCLC KRAS G12C , LUMAKRAS NSCLC , [ (14.1)] KRAS G12C (mCRC) KRAS G12C , (mCRC) [ (14.2)] FDA KRAS G12C

Langkah Berjaga-jaga

5 Langkah Berjaga-jaga 3 , 3 , , LUMAKRAS (2.3, 5.1) (ILD)/ ILD/ , LUMAKRAS ILD/ , (2.3, 5.2) 5.1 LUMAKRAS , (ALT) (AST) , LUMAKRAS 960 mg [ (6.1)],27% , 16% ≥10